Evidence map›Paper›PMID 38836441›Full record

ArticleGlycobiology2024

Modeling interactions between Heparan sulfate and proteins based on the Heparan sulfate microarray analysis.

Cleber C Melo-Filho, Guowei Su, Kevin Liu, Eugene N Muratov, Alexander Tropsha, Jian Liu

Abstract read
In one paragraph

Article in Glycobiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cleber C Melo-FilhoLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, 301 Beard Hall, University of North Carolina, Chapel Hill, NC 27599, United States.
Guowei SuGlycan Therapeutics, 617 Hutton Street, Raleigh, NC 27606, United States.
Kevin LiuGlycan Therapeutics, 617 Hutton Street, Raleigh, NC 27606, United States.
Eugene N MuratovLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, 301 Beard Hall, University of North Carolina, Chapel Hill, NC 27599, United States.
Alexander TropshaLaboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, 301 Beard Hall, University of North Carolina, Chapel Hill, NC 27599, United States.
Jian LiuDivision of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, 1044 Genetic Medicine Bldg., University of North Carolina, Chapel Hill, NC 27599, United States.ORCID 0000-0001-8552-1400

Funding

Developing Heparan Sulfate Glycan ArrayR44GM123792 · NIGMS · GLYCAN THERAPEUTICS CORPORATION · PI SU, GUOWEI · 2020 to 2021
$2.4M
NIGMS NIH HHS R44 GM123792NIH HHS R44GM123792
6 · The paper itself

Abstract

Heparan sulfate (HS), a sulfated polysaccharide abundant in the extracellular matrix, plays pivotal roles in various physiological and pathological processes by interacting with proteins. Investigating the binding selectivity of HS oligosaccharides to target proteins is essential, but the exhaustive inclusion of all possible oligosaccharides in microarray experiments is impractical. To address this challenge, we present a hybrid pipeline that integrates microarray and in silico techniques to design oligosaccharides with desired protein affinity. Using fibroblast growth factor 2 (FGF2) as a model protein, we assembled an in-house dataset of HS oligosaccharides on microarrays and developed two structural representations: a standard representation with all atoms explicit and a simplified representation with disaccharide units as "quasi-atoms." Predictive Quantitative Structure-Activity Relationship (QSAR) models for FGF2 affinity were developed using the Random Forest (RF) algorithm. The resulting models, considering the applicability domain, demonstrated high predictivity, with a correct classification rate of 0.81-0.80 and improved positive predictive values (PPV) up to 0.95. Virtual screening of 40 new oligosaccharides using the simplified model identified 15 computational hits, 11 of which were experimentally validated for high FGF2 affinity. This hybrid approach marks a significant step toward the targeted design of oligosaccharides with desired protein interactions, providing a foundation for broader applications in glycobiology.

Indexed as

Heparan SulfateMicroarray AnalysisModels, MolecularFibroblast Growth Factor 2HumansOligosaccharidesProtein BindingQuantitative Structure-Activity RelationshipFibroblast Growth Factor 2Heparan SulfateOligosaccharideschemoenzymatic synthesisGlycan microarrayheparinoligosaccharides

Identifiers

PMID38836441
PMCPMC11180703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.